# CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

> **NCT04266249** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 2175 (actual)

## Conditions studied

- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Invasive Breast Carcinoma
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8

## Interventions

- **DRUG:** Docetaxel
- **PROCEDURE:** Lumpectomy
- **PROCEDURE:** Mastectomy
- **DRUG:** Nab-paclitaxel
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pertuzumab
- **RADIATION:** Radiation Therapy
- **BIOLOGICAL:** Trastuzumab
- **BIOLOGICAL:** Trastuzumab Emtansine

## Key facts

- **NCT ID:** NCT04266249
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-13
- **Primary completion:** 2026-10-31
- **Final completion:** 2038-12-31
- **Target enrollment:** 2175 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04266249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04266249, "CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04266249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*